US EditionSimcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of ...
- Simcere Zaiming announced that the first US patient has begun treatment in a Phase 1 trial of SIM0500 at The Tisch Cancer Institute.
- The trial is assessing safety, tolerability, pharmacokinetics, and preliminary efficacy of SIM0500 for relapsed/refractory multiple myeloma.
- SIM0500 is designed to target two tumor antigens, GPRC5D and BCMA, potentially offering new options for drug resistance in existing treatments.
- Simcere Zaiming expressed satisfaction with the preliminary results and looks forward to expanding the trial in the US.
Insights by Ground AI
Does this summary seem wrong?
68 Articles
68 Articles
Fox 4 Kansas City+66 Reposted by 66 other sources
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
·Kansas City, United States
Read Full Article
Coverage Details
Total News Sources68
Leaning Left8Leaning Right3Center24Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 23%
C 69%
Factuality
To view factuality data please Upgrade to Premium
